Enoxolone

Enoxolone

Clinical data
Trade names	Arthrodont, PruClair
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, topical
ATC code	D03AX10 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
CAS Number	471-53-4
PubChem CID	10114
ChemSpider	9710
ChEBI	CHEBI:30853
ChEMBL	ChEMBL230006
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C30H46O4
Molar mass	470.6838
3D model (JSmol)	Interactive image
SMILES O=C(O)[C@]5(C)C[C@H]4/C3=C/C(=O)[C@H]1[C@](CC[C@@H]2[C@]1(C)CC[C@H](O)C2(C)C)(C)[C@]3(C)CC[C@@]4(C)CC5
InChI InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1 Key:MPDGHEJMBKOTSU-YKLVYJNSSA-N

WikiDoc Resources for Enoxolone
Articles
Most recent articles on Enoxolone Most cited articles on Enoxolone Review articles on Enoxolone Articles on Enoxolone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Enoxolone Images of Enoxolone Photos of Enoxolone Podcasts & MP3s on Enoxolone Videos on Enoxolone
Evidence Based Medicine
Cochrane Collaboration on Enoxolone Bandolier on Enoxolone TRIP on Enoxolone
Clinical Trials
Ongoing Trials on Enoxolone at Clinical Trials.gov Trial results on Enoxolone Clinical Trials on Enoxolone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Enoxolone NICE Guidance on Enoxolone NHS PRODIGY Guidance FDA on Enoxolone CDC on Enoxolone
Books
Books on Enoxolone
News
Enoxolone in the news Be alerted to news on Enoxolone News trends on Enoxolone
Commentary
Blogs on Enoxolone
Definitions
Definitions of Enoxolone
Patient Resources / Community
Patient resources on Enoxolone Discussion groups on Enoxolone Patient Handouts on Enoxolone Directions to Hospitals Treating Enoxolone Risk calculators and risk factors for Enoxolone
Healthcare Provider Resources
Symptoms of Enoxolone Causes & Risk Factors for Enoxolone Diagnostic studies for Enoxolone Treatment of Enoxolone
Continuing Medical Education (CME)
CME Programs on Enoxolone
International
Enoxolone en Espanol Enoxolone en Francais
Business
Enoxolone in the Marketplace Patents on Enoxolone
Experimental / Informatics
List of terms related to Enoxolone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Enoxolone (INN, BAN), glycyrrhetinic acid or glycyrrhetic acid is a pentacyclic triterpenoid derivative of the beta-amyrin type obtained from the hydrolysis of glycyrrhizic acid, which was obtained from the herb liquorice. It is used in flavoring and it masks the bitter taste of drugs like aloe and quinine. It is effective in the treatment of peptic ulcer and also has expectorant (antitussive) properties. It has some additional pharmacological properties including antiviral, antifungal, antiprotozoal, and antibacterial activities.

Mechanism of action

Glycyrrhetinic acid inhibits the enzymes (15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin) that metabolize the prostaglandins PGE-2 and PGF-2α to their respective 15-keto-13,14-dihydro metabolites which are inactive. This causes an increased level of prostaglandins in the digestive system. Prostaglandins inhibit gastric secretion but stimulate pancreatic secretion and mucous secretion in the intestines and markedly increase intestinal motility. They also cause cell proliferation in the stomach. The effect on gastric acid secretion, promotion of mucous secretion and cell proliferation shows why licorice has potential in treating peptic ulcer.

PGF-2α stimulates activity of the uterus during pregnancy and can cause abortion, therefore, licorice should not be taken during pregnancy.

The structure of glycyrrhetinic acid is similar to that of cortisone. Both molecules are flat and similar at position 3 and 11. This might be the basis for licorice's anti-inflammatory action.

3-β-D-(Monoglucuronyl)-18-β-glycyrrhetinic acid, a metabolite of glycyrrhetinic acid, inhibits the conversion of 'active' cortisol to 'inactive' cortisone in the kidneys. This occurs via inhibition of the enzyme by inhibiting the enzyme 11-β-hydroxysteroid dehydrogenase. As a result, cortisol levels are high within the collecting duct of the kidney. Cortisol has intrinsic mineralocorticoid properties (that is, it acts like aldosterone and increases sodium reabsorption) that work on ENaC channels in the collecting duct. Hypertension develops due to this mechanism of sodium retention. People often have high blood pressure with a low renin and low aldosterone blood level. The increased amounts of cortisol binds to the unprotected, unspecific mineralocorticoid receptors and induce sodium and fluid retention, hypokalaemia, high blood pressure and inhibition of the renin-angiotensin-aldosterone system. Therefore licorice should not be given to patients with a known history of hypertension in doses sufficient to inhibit 11-β-hydroxysteroid dehydrogenase.

Derivatives

Glycyrrhetinic acid derivatives, where R is a variable functional group

In glycyrrhetinic acid, the functional group (R) is a hydroxyl group. Research in 2005 demonstrated that with a proper functional group a very effective glycyrrhetinic artificial sweetener can be obtained. When R is an anionic NHCO(CH₂)CO₂K side chain, the sweetening effect is found to 1200 times that of sugar (human sensory panel data). A shorter or longer spacer reduces the sweetening effect. One explanation is that the taste bud cell receptor has 1.3 nanometers (13 angstroms) available for docking with the sweetener molecule. In addition the sweetener molecule requires three proton donor positions of which two reside at the extremities to be able to interact efficiently with the receptor cavity.

A synthetic analog, carbenoxolone, was developed in Britain. Both glycyrrhetinic acid and carbenoxolone have a modulatory effect on neural signaling through gap junction channels.

Acetoxolone, the acetyl derivative of glycyrrhetinic acid, is a drug used in the treatment of peptic ulcer and gastroesophageal reflux disease.

Further reading

• Saponin Glycosides, by Georges-Louis Friedli, URL accessed Sept 2010.

Template:Preparations for treatment of wounds and ulcers